Sherif R Aboseif, MD
Urology · Oxnard
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 45 years
- Graduated 1981
Offices
2 locations · Sherif Aboseif MD Inc · Genesis Healthcare Partners PC
Hospitals listed: St Johns Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Aboseif’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A48911 · Current
Licensed to practise in California · since 1990 · expires 2028-09-30 · Ain Shams University Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- St Johns Regional Medical CenterOxnard, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.06 (90.32 to 169.81) · 120 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.404, Oct 2024 – Sep 2025
See every measure and the patient survey for St Johns Regional Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.06 (90.32 to 169.81) · 120 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.404 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.8 (0 to 1.75) · 1,494 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.56 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 159 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 8.7 · 279 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.1 · 580 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.6 · 654 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,404 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.37) · 8,124 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.39) · 8,331 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.92 (1.89 to 5.95) · 1,414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.17 (0.6 to 3.75) · 412 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.94 (0.46 to 3.43) · 1,361 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.75 (0.73 to 12.78) · 439 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.94 (3.39 to 10.49) · 383 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.94 (0.47 to 3.41) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.11 (0 to 0.67) · 7,172 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 88 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.236 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.331 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.571 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.737 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 336 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.8 · 715 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -8.1 · 284 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.6 · 648 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -9.1 · 674 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.9 · 670 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (5.2 to 8.9) · 428 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (8.6 to 13.5) · 428 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.9 · 98 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 196 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.5 to 18.8) · 247 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 486 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,151 patients answered, 18% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$498,958
Medicare paid this office $498,958 for 884 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 212 | $103,575 | $348 |
| Short return visit (20+ min) | 591 | $99,813 | $72 |
| Insertion of device into abdomen with pressure and urine flow rate study | 139 | $39,053 | $184 |
| Injection procedure for imaging of bladder during voiding | 226 | $30,708 | $97 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 24 | $26,163 | None |
See all 28 services
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 212 | $103,575 | $348 |
| Short return visit (20+ min) | 591 | $99,813 | $72 |
| Insertion of device into abdomen with pressure and urine flow rate study | 139 | $39,053 | $184 |
| Injection procedure for imaging of bladder during voiding | 226 | $30,708 | $97 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 24 | $26,163 | None |
| New patient visit (45+ min) | 186 | $22,261 | $120 |
| Diagnostic exam of bladder and urethra using an endoscope | 65 | $14,743 | $208 |
| Return visit (30+ min) | 145 | $12,295 | $75 |
| Dilation of urethra using an endoscope | 36 | $11,035 | $290 |
| Electronic assessment of bladder emptying | 459 | $9,810 | $10 |
| Complicated change of bladder tube | 12 | $9,516 | $120 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 211 | $8,834 | $30 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $7,786 | $144 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 12 | $7,299 | $608 |
| Ultrasound measurement of bladder capacity after voiding | 317 | $6,729 | $10 |
| Complicated insertion of bladder tube | 23 | $6,413 | $128 |
| Imaging guidance for procedure, 60 minutes or less | 126 | $6,304 | $40 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $4,574 | $104 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 17 | $4,360 | $256 |
| Ultrasound scan of pelvic region through rectum | 24 | $3,166 | $132 |
| Biopsy of prostate gland | 15 | $2,893 | $193 |
| Simple insertion of temporary bladder tube | 13 | $2,196 | $59 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 23 | $2,103 | $46 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 24 | $1,841 | $29 |
| Injection procedure to cause erection | 20 | $1,667 | $64 |
| Complicated insertion of bladder tube | 14 | $893 | $64 |
| Injection of drug or substance under skin or into muscle | 17 | $350 | $12 |
| Injection, garamycin, gentamicin, up to 80 mg | 18 | $66 | None |
Procedures Medicare counted
| Prostate resection | 15 | More than 70% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Electronic assessment of bladder emptying | 970 | 848 | 1,003 | 1,064 | 1,042 | 971 |
| Ultrasound measurement of bladder capacity after voiding | 677 | 568 | 709 | 737 | 731 | 677 |
| Injection procedure for imaging of bladder during voiding | 255 | 254 | 281 | 304 | 321 | 316 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 248 | 244 | 272 | 291 | 306 | 298 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 248 | 244 | 268 | 289 | 306 | 297 |
| Insertion of device into abdomen with pressure and urine flow rate study | 163 | 141 | 139 | 187 | 207 | 212 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
884 Original Medicare patients in 2024. Average age 76 · Under 65 6% · 85 and older 22% · Women 27% · Also on Medicaid 31% · Health risk score 1.63. Above the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Diabetes 45% · Coronary heart disease 42% · Chronic kidney disease 35% · Depression 27% · Heart failure 26% · Atrial fibrillation 25% · Cancer 21% · COPD 19% · Stroke 14% · Dementia 13%.
The office billed $1,611,385, Medicare allowed $660,428 and paid $498,958; for 14,937 services of 78 kinds; $41,658 of it was for drugs given in the office and $457,300 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 884 | 14,937 | 76 | 1.63 | $1,611,385 | $498,958 |
| 2023 | 1,229 | 12,023 | 76 | 1.61 | $2,314,221 | $760,709 |
| 2022 | 1,070 | 9,421 | 76 | 1.58 | $2,182,385 | $711,115 |
| 2021 | 949 | 11,739 | 76 | 1.69 | $1,925,568 | $635,520 |
| 2020 | 769 | 13,350 | 76 | 1.85 | $1,569,411 | $488,772 |
| 2019 | 820 | 12,515 | 75 | 1.95 | $1,687,202 | $489,603 |
| 2018 | 810 | 13,846 | 75 | 1.80 | $1,628,885 | $448,381 |
| 2017 | 865 | 7,789 | 75 | 1.74 | $1,773,271 | $494,339 |
| 2016 | 802 | 6,743 | 73 | 1.73 | $1,560,556 | $445,261 |
| 2015 | 855 | 8,104 | 74 | 1.67 | $1,999,030 | $574,786 |
| 2014 | 813 | 6,791 | 74 | 1.54 | $1,801,353 | $518,289 |
| 2013 | 560 | 5,789 | 74 | 1.56 | $1,514,173 | $438,314 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 33 services
| Short return visit (20+ min) | 849 | $148,440 | $72 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 257 | $103,852 | $339 |
| New patient visit (45+ min) | 442 | $56,815 | $129 |
| Return visit (30+ min) | 293 | $47,878 | $109 |
| Diagnostic exam of bladder and urethra using an endoscope | 182 | $43,915 | $217 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 36 | $38,354 | None |
| Insertion of device into abdomen with pressure and urine flow rate study | 169 | $37,504 | $181 |
| Injection procedure for imaging of bladder during voiding | 267 | $31,453 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 95 | $27,745 | $99 |
| Dilation of urethra using an endoscope | 55 | $17,578 | $279 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 119 | $17,100 | $140 |
| Complicated change of bladder tube | 15 | $14,839 | $117 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 21 | $12,702 | $605 |
| Imaging guidance for procedure, 60 minutes or less | 257 | $12,185 | $40 |
| Complicated insertion of bladder tube | 30 | $10,715 | $132 |
| Electronic assessment of bladder emptying | 514 | $10,186 | $10 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 257 | $8,742 | $29 |
| Ultrasound scan of pelvic region through rectum | 64 | $8,384 | $125 |
| Shock wave crushing of kidney stones | 17 | $8,383 | $493 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 24 | $6,942 | $289 |
| Ultrasound measurement of bladder capacity after voiding | 334 | $6,733 | $9 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 18 | $6,377 | $336 |
| Biopsy of prostate gland | 28 | $6,294 | $217 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 20 | $4,990 | $250 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 36 | $2,698 | $28 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 23 | $2,214 | $46 |
| Injection procedure to cause erection | 19 | $1,657 | $72 |
| Complicated insertion of bladder tube | 20 | $1,465 | $64 |
| Insertion of temporary bladder tube | 34 | $1,270 | $32 |
| Insertion of stent in ureter using an endoscope | 11 | $1,261 | $115 |
| Injection of drug or substance under skin or into muscle | 39 | $518 | $13 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $494 | $45 |
| Injection, garamycin, gentamicin, up to 80 mg | 42 | $108 | None |
2022: 33 services
| Short return visit (20+ min) | 847 | $154,305 | $73 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 250 | $101,701 | $349 |
| New patient visit (45+ min) | 381 | $50,686 | $133 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 35 | $39,496 | None |
| Insertion of device into abdomen with pressure and urine flow rate study | 149 | $35,371 | $189 |
| Diagnostic exam of bladder and urethra using an endoscope | 142 | $33,512 | $222 |
| Injection procedure for imaging of bladder during voiding | 260 | $30,395 | $100 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 34 | $20,897 | $615 |
| Dilation of urethra using an endoscope | 62 | $20,554 | $289 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 110 | $19,286 | $166 |
| Complicated change of bladder tube | 13 | $15,382 | $122 |
| Imaging guidance for procedure, 60 minutes or less | 250 | $11,594 | $40 |
| Ultrasound scan of pelvic region through rectum | 88 | $11,047 | $126 |
| Electronic assessment of bladder emptying | 522 | $10,585 | $10 |
| Complicated insertion of bladder tube | 27 | $9,537 | $138 |
| Return visit (30+ min) | 80 | $9,029 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $8,512 | $86 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 250 | $8,338 | $29 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 23 | $7,140 | $298 |
| Ultrasound measurement of bladder capacity after voiding | 321 | $6,819 | $9 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 14 | $5,378 | $359 |
| Shock wave crushing of kidney stones | 11 | $5,233 | $476 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 19 | $5,041 | $240 |
| Biopsy of prostate gland | 20 | $4,274 | $214 |
| Insertion of temporary bladder tube | 93 | $4,115 | $35 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 35 | $2,664 | $28 |
| Insertion of stent in ureter using an endoscope | 21 | $2,332 | $111 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 24 | $2,326 | $48 |
| Injection procedure to cause erection | 20 | $1,497 | $62 |
| Complicated insertion of bladder tube | 19 | $1,233 | $65 |
| Imaging of urinary tract following injection of a contrast agent | 13 | $273 | $21 |
| Injection of drug or substance under skin or into muscle | 11 | $193 | $13 |
| Injection, garamycin, gentamicin, up to 80 mg | 13 | $30 | None |
2021: 30 services
| Short return visit (20+ min) | 761 | $138,592 | $74 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 240 | $94,000 | $346 |
| New patient visit (45+ min) | 293 | $39,005 | $133 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 35 | $38,622 | None |
| Injection procedure for imaging of bladder during voiding | 245 | $28,452 | $101 |
| Diagnostic exam of bladder and urethra using an endoscope | 123 | $27,760 | $215 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 137 | $24,653 | $170 |
| Insertion of device into abdomen with pressure and urine flow rate study | 120 | $24,498 | $176 |
| Dilation of urethra using an endoscope | 66 | $21,456 | $294 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 29 | $17,993 | $620 |
| Electronic assessment of bladder emptying | 494 | $10,105 | $10 |
| Ultrasound scan of pelvic region through rectum | 75 | $9,898 | $130 |
| Return visit (30+ min) | 74 | $8,419 | $108 |
| Complicated change of bladder tube | 11 | $8,167 | $122 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 239 | $7,915 | $30 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $7,238 | $88 |
| Ultrasound measurement of bladder capacity after voiding | 316 | $6,383 | $9 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 22 | $6,083 | $264 |
| Imaging guidance for procedure, 60 minutes or less | 128 | $5,470 | $39 |
| Insertion of temporary bladder tube | 103 | $5,240 | $39 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 16 | $5,220 | $290 |
| Biopsy of prostate gland | 16 | $3,695 | $217 |
| Complicated insertion of bladder tube | 17 | $3,537 | $131 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 35 | $2,534 | $28 |
| Insertion of stent in ureter using an endoscope | 20 | $2,406 | $115 |
| Injection procedure to cause erection | 23 | $1,906 | $76 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 17 | $1,599 | $48 |
| Complicated insertion of bladder tube | 16 | $1,179 | $65 |
| Imaging of urinary tract following injection of a contrast agent | 13 | $280 | $22 |
| Injection, garamycin, gentamicin, up to 80 mg | 12 | $42 | None |
2020: 26 services
| Short return visit (20+ min) | 611 | $83,845 | $58 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 209 | $80,788 | $331 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 40 | $46,343 | None |
| New patient visit (45+ min) | 200 | $25,578 | $128 |
| Injection procedure for imaging of bladder during voiding | 215 | $23,129 | $91 |
| Insertion of device into abdomen with pressure and urine flow rate study | 118 | $21,661 | $154 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 26 | $16,775 | $645 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 87 | $16,282 | $173 |
| Diagnostic exam of bladder and urethra using an endoscope | 69 | $14,280 | $185 |
| Dilation of urethra using an endoscope | 44 | $14,205 | $290 |
| Ultrasound scan of pelvic region through rectum | 90 | $11,817 | $131 |
| Electronic assessment of bladder emptying | 454 | $8,284 | $10 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 209 | $7,489 | $31 |
| Shock wave crushing of kidney stones | 13 | $6,397 | $492 |
| Imaging guidance for procedure, 60 minutes or less | 127 | $5,539 | $38 |
| Ultrasound measurement of bladder capacity after voiding | 295 | $4,768 | $8 |
| Biopsy of prostate gland | 18 | $4,139 | $230 |
| Return visit (30+ min) | 35 | $3,626 | $88 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 12 | $3,141 | $262 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 40 | $2,465 | $26 |
| Insertion of temporary bladder tube | 57 | $2,306 | $38 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,080 | $90 |
| Telephone medical discussion with physician, 21-30 minutes | 25 | $1,504 | $58 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 12 | $1,270 | $49 |
| Injection procedure to cause erection | 14 | $1,263 | $79 |
| Injection, garamycin, gentamicin, up to 80 mg | 11 | $18 | None |
2019: 26 services
| Short return visit (20+ min) | 680 | $90,896 | $58 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 225 | $76,921 | $310 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 34 | $36,259 | None |
| New patient visit (45+ min) | 230 | $28,202 | $123 |
| Injection procedure for imaging of bladder during voiding | 231 | $22,379 | $88 |
| Insertion of device into abdomen with pressure and urine flow rate study | 144 | $20,982 | $129 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 93 | $18,428 | $171 |
| Dilation of urethra using an endoscope | 58 | $16,604 | $268 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 26 | $16,456 | $633 |
| Diagnostic exam of bladder and urethra using an endoscope | 84 | $15,570 | $169 |
| Ultrasound scan of pelvic region through rectum | 113 | $13,749 | $118 |
| Insertion of sacral nerve neurostimulator electrode array | 12 | $11,937 | $995 |
| Imaging guidance for procedure, 60 minutes or less | 222 | $10,525 | $43 |
| Electronic assessment of bladder emptying | 508 | $9,928 | $10 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 225 | $7,544 | $30 |
| Ultrasound measurement of bladder capacity after voiding | 332 | $7,302 | $11 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 22 | $5,697 | $259 |
| Insertion of temporary bladder tube | 103 | $5,273 | $39 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $4,580 | $88 |
| Biopsy of prostate gland | 20 | $4,506 | $225 |
| Return visit (30+ min) | 38 | $4,042 | $90 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 34 | $1,787 | $26 |
| Injection procedure to cause erection | 22 | $1,744 | $76 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 16 | $1,450 | $47 |
| Complicated insertion of bladder tube | 11 | $1,182 | $107 |
| Injection, garamycin, gentamicin, up to 80 mg | 14 | $19 | None |
2018: 29 services
| Short return visit (20+ min) | 667 | $89,042 | $57 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 222 | $69,119 | $290 |
| New patient visit (45+ min) | 192 | $25,231 | $131 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 106 | $19,892 | $166 |
| Injection procedure for imaging of bladder during voiding | 225 | $19,844 | $81 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 26 | $18,841 | None |
| Insertion of device into abdomen with pressure and urine flow rate study | 124 | $13,951 | $103 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 21 | $12,986 | $618 |
| Dilation of urethra using an endoscope | 45 | $12,325 | $242 |
| Diagnostic exam of bladder and urethra using an endoscope | 67 | $11,077 | $144 |
| Electronic assessment of bladder emptying | 486 | $10,153 | $11 |
| Imaging guidance for procedure, 60 minutes or less | 213 | $9,926 | $44 |
| Ultrasound measurement of bladder capacity after voiding | 316 | $8,477 | $13 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 222 | $7,312 | $31 |
| Ultrasound scan of pelvic region through rectum | 78 | $6,872 | $87 |
| Complicated change of bladder tube | 11 | $6,101 | $111 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 23 | $6,012 | $250 |
| Return visit (30+ min) | 59 | $5,885 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 38 | $5,678 | $87 |
| Insertion of temporary bladder tube | 89 | $4,284 | $41 |
| Biopsy of prostate gland | 18 | $3,820 | $212 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 22 | $1,933 | $48 |
| Injection procedure to cause erection | 24 | $1,791 | $72 |
| Insertion of stent in ureter using an endoscope | 14 | $1,669 | $119 |
| Complicated insertion of bladder tube | 24 | $1,572 | $65 |
| Insertion or replacement of peripheral, sacral, or gastric neurostimulator generator or receiver | 13 | $1,332 | $102 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 26 | $977 | $26 |
| Automated urinalysis test | 18 | $54 | $3 |
| Injection, garamycin, gentamicin, up to 80 mg | 12 | $16 | None |
2017: 30 services
| Short return visit (20+ min) | 698 | $93,383 | $56 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 250 | $75,857 | $285 |
| New patient visit (45+ min) | 230 | $28,395 | $123 |
| Injection procedure for imaging of bladder during voiding | 254 | $21,645 | $80 |
| Insertion of sacral nerve neurostimulator electrode array | 20 | $21,172 | $1,059 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 93 | $17,565 | $167 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 24 | $17,238 | $718 |
| Dilation of urethra using an endoscope | 59 | $15,424 | $237 |
| Insertion of device into abdomen with pressure and urine flow rate study | 137 | $15,175 | $101 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 20 | $12,910 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 77 | $12,806 | $142 |
| Imaging guidance for procedure, 60 minutes or less | 240 | $11,093 | $43 |
| Electronic assessment of bladder emptying | 524 | $10,121 | $11 |
| Ultrasound measurement of bladder capacity after voiding | 320 | $9,881 | $16 |
| Return visit (30+ min) | 88 | $8,816 | $87 |
| Botox | 12 | $8,441 | None |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 250 | $8,150 | $31 |
| Ultrasound scan of pelvic region through rectum | 80 | $6,968 | $85 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 25 | $6,420 | $257 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 12 | $4,619 | $272 |
| Insertion of temporary bladder tube | 97 | $4,553 | $39 |
| Biopsy of prostate gland | 15 | $3,521 | $220 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,174 | $84 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 28 | $2,467 | $50 |
| Injection procedure to cause erection | 28 | $2,139 | $74 |
| Complicated insertion of bladder tube | 16 | $1,079 | $63 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 20 | $707 | $27 |
| Injection of drug or substance under skin or into muscle | 15 | $461 | $23 |
| Automated urinalysis test | 46 | $205 | $3 |
| Injection, garamycin, gentamicin, up to 80 mg | 15 | $24 | None |
2016: 28 services
| Short return visit (20+ min) | 630 | $86,966 | $56 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 206 | $62,365 | $278 |
| New patient visit (45+ min) | 237 | $29,932 | $126 |
| Destruction of prostate tissue using microwave induced heat | 13 | $24,450 | $1,881 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 206 | $18,884 | $84 |
| Injection procedure for imaging of bladder during voiding | 201 | $17,695 | $80 |
| Diagnostic exam of bladder and urethra using an endoscope | 82 | $15,416 | $175 |
| Insertion of device into abdomen with pressure and urine flow rate study | 126 | $14,286 | $99 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 20 | $13,879 | $694 |
| Dilation of urethra using an endoscope | 54 | $13,679 | $228 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $11,529 | None |
| Electronic assessment of bladder emptying | 493 | $10,541 | $11 |
| Ultrasound measurement of bladder capacity after voiding | 334 | $10,434 | $16 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $10,038 | $167 |
| Return visit (30+ min) | 91 | $9,480 | $87 |
| Imaging guidance for procedure, 60 minutes or less | 188 | $8,734 | $42 |
| Ultrasound scan of pelvic region through rectum | 102 | $8,702 | $83 |
| Insertion of temporary bladder tube | 91 | $4,869 | $47 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 24 | $4,563 | $190 |
| Biopsy of prostate gland | 17 | $3,439 | $191 |
| Complicated insertion of bladder tube | 15 | $2,834 | $109 |
| Injection procedure to cause erection | 25 | $1,725 | $69 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 17 | $1,307 | $50 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,297 | $59 |
| Ultrasonic guidance for needle placement | 19 | $1,127 | $51 |
| Complicated insertion of bladder tube | 12 | $908 | $65 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $579 | $28 |
| Automated urinalysis test | 57 | $213 | $3 |
2015: 33 services
| Short return visit (20+ min) | 702 | $102,885 | $57 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 274 | $81,272 | $280 |
| New patient visit (45+ min) | 332 | $43,472 | $131 |
| Destruction of prostate tissue using microwave induced heat | 14 | $26,295 | $1,878 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 274 | $24,721 | $85 |
| Diagnostic exam of bladder and urethra using an endoscope | 123 | $24,035 | $177 |
| Injection procedure for imaging of bladder during voiding | 276 | $23,700 | $80 |
| Insertion of device into abdomen with pressure and urine flow rate study | 201 | $21,222 | $99 |
| Dilation of urethra using an endoscope | 83 | $21,129 | $237 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 30 | $20,950 | $698 |
| Insertion of sacral nerve neurostimulator electrode array | 13 | $14,349 | $1,104 |
| Return visit (30+ min) | 134 | $13,942 | $81 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 21 | $13,431 | None |
| Electronic assessment of bladder emptying | 563 | $12,446 | $11 |
| Ultrasound scan of pelvic region through rectum | 142 | $12,042 | $82 |
| Imaging guidance for procedure, 60 minutes or less | 262 | $11,743 | $42 |
| Ultrasound measurement of bladder capacity after voiding | 370 | $11,587 | $16 |
| Insertion of temporary bladder tube | 125 | $6,562 | $47 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,040 | $168 |
| Biopsy of prostate gland | 24 | $4,391 | $183 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 17 | $3,793 | $223 |
| Complicated insertion of bladder tube | 13 | $3,601 | $113 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 31 | $3,062 | $85 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,424 | $115 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 24 | $1,740 | $47 |
| Injection procedure to cause erection | 18 | $1,428 | $71 |
| Ultrasonic guidance for needle placement | 25 | $1,378 | $49 |
| Fluoroscopic guidance for needle placement | 13 | $1,026 | $79 |
| Complicated insertion of bladder tube | 13 | $802 | $62 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $673 | $27 |
| Injection of drug or substance under skin or into muscle | 14 | $317 | $23 |
| Automated urinalysis test | 80 | $306 | $3 |
| Injection, garamycin, gentamicin, up to 80 mg | 14 | $15 | None |
2014: 28 services
| Short return visit (20+ min) | 562 | $78,119 | $58 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 253 | $73,573 | $277 |
| New patient visit (45+ min) | 477 | $61,719 | $129 |
| Insertion of device into abdomen with pressure and urine flow rate study | 253 | $25,950 | $98 |
| Diagnostic exam of bladder and urethra using an endoscope | 135 | $24,413 | $171 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 253 | $22,367 | $84 |
| Injection procedure for imaging of bladder during voiding | 254 | $21,746 | $81 |
| Destruction of prostate tissue using microwave induced heat | 11 | $19,096 | $1,736 |
| Dilation of urethra using an endoscope | 74 | $18,807 | $229 |
| Ultrasound scan of pelvic region through rectum | 203 | $17,033 | $83 |
| Insertion of sacral nerve neurostimulator electrode array | 13 | $13,668 | $651 |
| Imaging guidance for procedure, 60 minutes or less | 232 | $11,196 | $46 |
| Return visit (30+ min) | 94 | $10,682 | $90 |
| Electronic assessment of bladder emptying | 511 | $10,455 | $11 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $9,156 | $170 |
| Ultrasound measurement of bladder capacity after voiding | 316 | $8,653 | $16 |
| Insertion of temporary bladder tube | 128 | $7,323 | $46 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 27 | $6,819 | $253 |
| Creation of sling around urethra in female to control leakage | 11 | $5,726 | $521 |
| Biopsy of prostate gland | 21 | $3,966 | $189 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 20 | $2,729 | $91 |
| Injection procedure to cause erection | 29 | $2,264 | $78 |
| Ultrasonic guidance for needle placement | 19 | $1,374 | $65 |
| Fluoroscopic guidance for needle placement | 13 | $1,002 | $77 |
| Short return visit | 13 | $647 | $36 |
| Automated urinalysis test | 135 | $540 | $3 |
| Injection of drug or substance under skin or into muscle | 12 | $270 | $22 |
| Injection, garamycin, gentamicin, up to 80 mg | 12 | $12 | None |
2013: 25 services
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 249 | $73,265 | $287 |
| Short return visit (20+ min) | 374 | $55,795 | $59 |
| New patient visit (45+ min) | 298 | $37,503 | $126 |
| Insertion of device into abdomen with pressure and urine flow rate study | 249 | $26,113 | $102 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 249 | $22,221 | $87 |
| Injection procedure for imaging of bladder during voiding | 231 | $20,064 | $84 |
| Diagnostic exam of bladder and urethra using an endoscope | 112 | $19,968 | $166 |
| Dilation of urethra using an endoscope | 82 | $19,144 | $213 |
| Imaging guidance for procedure, 60 minutes or less | 222 | $11,095 | $49 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 59 | $9,939 | $163 |
| Return visit (30+ min) | 85 | $8,795 | $87 |
| Ultrasound scan of pelvic region through rectum | 127 | $8,365 | $65 |
| Electronic assessment of bladder emptying | 370 | $8,026 | $11 |
| Insertion of temporary bladder tube | 114 | $7,662 | $48 |
| Ultrasound measurement of bladder capacity after voiding | 207 | $7,123 | $17 |
| Creation of sling around urethra in female to control leakage | 15 | $6,549 | $437 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 19 | $4,125 | $217 |
| Short return visit | 40 | $2,690 | $36 |
| Injection procedure to cause erection | 20 | $1,543 | $77 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 12 | $1,406 | $78 |
| Automated urinalysis test | 254 | $1,269 | $3 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $882 | $59 |
| Injection of drug or substance under skin or into muscle | 18 | $586 | $23 |
| Injection, garamycin, gentamicin, up to 80 mg | 17 | $20 | None |
| Injection, papaverine hcl, up to 60 mg | 14 | $14 | None |
Medicaid work
$21,034 in 2024
Medicaid paid $21,034 for 275 billed services this clinician did in 2024, up to 26 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 176 | $11,620 |
| Return visit (30+ min) | 40 | $5,685 |
| New patient visit (45+ min) | 17 | $3,152 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 29 | $407 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 13 | $169 |
| 2024 | 275 | 5 | 26 | $21,034 |
| 2023 | 1,238 | 9 | 63 | $133,301 |
| 2022 | 2,032 | 10 | 79 | $209,014 |
| 2021 | 2,659 | 12 | 107 | $232,099 |
| 2020 | 2,217 | 12 | 94 | $187,223 |
| 2019 | 2,890 | 11 | 95 | $206,419 |
| 2018 | 2,629 | 12 | 101 | $103,361 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 542 | $54,421 |
| New patient visit (45+ min) | 220 | $40,450 |
| Return visit (30+ min) | 122 | $17,247 |
| Complex cystometrogram (ie, calibrated electronic equipment); with voiding pressure studies (ie, bladder voiding pressure), any technique | 27 | $11,949 |
| CYSTOURETHROSCOPY | 12 | $3,060 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 206 | $2,581 |
| Fluoroscopy (separate procedure), up to 1 hour physician or other qualified health care professional time | 41 | $2,076 |
| ANAL/URINARY MUSCLE STUDY | 27 | $977 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 41 | $540 |
2022
| Short return visit (20+ min) | 780 | $76,446 |
| New patient visit (45+ min) | 295 | $54,212 |
| Complex cystometrogram (ie, calibrated electronic equipment); with voiding pressure studies (ie, bladder voiding pressure), any technique | 99 | $42,469 |
| Injection procedure for voiding urethrocystography | 93 | $14,316 |
| Fluoroscopy (separate procedure), up to 1 hour physician or other qualified health care professional time | 142 | $6,768 |
| ANAL/URINARY MUSCLE STUDY | 105 | $4,523 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 354 | $4,478 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $2,590 |
| Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine) | 34 | $1,741 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 118 | $1,470 |
2021
| Short return visit (20+ min) | 1,095 | $104,112 |
| New patient visit (45+ min) | 259 | $44,319 |
| Complex cystometrogram (ie, calibrated electronic equipment); with voiding pressure studies (ie, bladder voiding pressure), any technique | 101 | $37,102 |
| Injection procedure for voiding urethrocystography | 101 | $12,276 |
| CYSTOURETHROSCOPY | 39 | $9,192 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 521 | $6,682 |
| 1ST HOSP IP/OBS HIGH 75 | 25 | $4,832 |
| ANAL/URINARY MUSCLE STUDY | 105 | $4,245 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 344 | $4,048 |
| INTRAABDOMINAL PRESSURE TEST | 16 | $2,725 |
| Fluoroscopy (separate procedure), up to 1 hour physician or other qualified health care professional time | 40 | $1,942 |
| Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine) | 13 | $624 |
2020
| Short return visit (20+ min) | 830 | $66,655 |
| Complex cystometrogram (ie, calibrated electronic equipment); with voiding pressure studies (ie, bladder voiding pressure), any technique | 151 | $57,089 |
| Injection procedure for voiding urethrocystography | 140 | $17,716 |
| New patient visit (45+ min) | 91 | $16,034 |
| ANAL/URINARY MUSCLE STUDY | 148 | $7,395 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $6,633 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 466 | $6,005 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 268 | $3,179 |
| Fluoroscopy (separate procedure), up to 1 hour physician or other qualified health care professional time | 68 | $3,044 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $2,023 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 17 | $967 |
| Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic | 13 | $482 |
2019
| Short return visit (20+ min) | 985 | $71,117 |
| Complex cystometrogram (ie, calibrated electronic equipment); with voiding pressure studies (ie, bladder voiding pressure), any technique | 191 | $58,732 |
| New patient visit (45+ min) | 124 | $20,609 |
| Injection procedure for voiding urethrocystography | 180 | $18,082 |
| Fluoroscopy (separate procedure), up to 1 hour physician or other qualified health care professional time | 179 | $7,806 |
| ANAL/URINARY MUSCLE STUDY | 191 | $7,231 |
| INTRAABDOMINAL PRESSURE TEST | 53 | $6,898 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 578 | $6,816 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 357 | $4,561 |
| 1ST HOSP IP/OBS HIGH 75 | 25 | $3,283 |
| Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine) | 27 | $1,284 |
2018
| Complex cystometrogram (ie, calibrated electronic equipment); with voiding pressure studies (ie, bladder voiding pressure), any technique | 176 | $27,925 |
| Short return visit (20+ min) | 878 | $25,846 |
| New patient visit (45+ min) | 198 | $19,226 |
| Injection procedure for voiding urethrocystography | 168 | $10,509 |
| ANAL/URINARY MUSCLE STUDY | 175 | $5,320 |
| Fluoroscopy (separate procedure), up to 1 hour physician or other qualified health care professional time | 170 | $3,780 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 508 | $3,217 |
| 1ST HOSP IP/OBS HIGH 75 | 25 | $2,673 |
| CYSTOSCOPY AND TREATMENT | 15 | $2,273 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 273 | $1,392 |
| Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine) | 29 | $656 |
| INTRAABDOMINAL PRESSURE TEST | 14 | $546 |
Drugs they prescribed that Part D paid
$421,160
Pharmacies billed $421,160 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (45 of 2,242) in 2024. At or below the middle of the specialty; the typical urology clinician is at 2%.
2,138 generic and fewer than 11 brand-name prescriptions · $421,160 in drug cost · 375 antibiotic prescriptions to 247 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 67 | $46,629 | $696 |
| Alfuzosin Hcl Er | 579 | $12,365 | $21 |
| Silodosin | 108 | $11,022 | $102 |
| Methenamine Hippurate | 127 | $8,802 | $69 |
| Tamsulosin | 369 | $6,512 | $18 |
See all 18 drugs
| Myrbetriq | 67 | $46,629 | $696 |
| Alfuzosin Hcl Er | 579 | $12,365 | $21 |
| Silodosin | 108 | $11,022 | $102 |
| Methenamine Hippurate | 127 | $8,802 | $69 |
| Tamsulosin | 369 | $6,512 | $18 |
| Solifenacin | 84 | $3,804 | $45 |
| Finasteride | 218 | $3,549 | $16 |
| Nitrofurantoin | 62 | $3,131 | $51 |
| Fesoterodine Fumarate Er | 20 | $3,062 | $153 |
| Estradiol | 64 | $3,020 | $47 |
| Tolterodine Tartrate Er | 11 | $2,607 | $237 |
| Oxybutynin Chloride Er | 55 | $994 | $18 |
| Nitrofurantoin Mono-Macro | 68 | $838 | $12 |
| Cephalexin | 27 | $574 | $21 |
| Sulfamethoxazole-Trimethoprim | 122 | $429 | $4 |
| Ciprofloxacin | 80 | $400 | $5 |
| Hydrocodone-Acetaminophen | 43 | $146 | $3 |
| Terazosin | 12 | $100 | $8 |
Year by year
| 2024 | 2,242 | 654 | 2% (45) | None | $421,160 |
| 2023 | 1,957 | 593 | 2% (39) | None | $430,472 |
| 2022 | 1,750 | 551 | 4% (64) | None | $520,669 |
| 2021 | 1,582 | 476 | 3% (54) | None | $514,156 |
| 2020 | 1,562 | 442 | 3% (51) | None | $456,381 |
| 2019 | 1,371 | 409 | 3% (42) | None | $338,625 |
| 2018 | 1,319 | 378 | 3% (44) | 26% | $333,815 |
| 2017 | 1,504 | 388 | 3% (45) | 22% | $247,968 |
| 2016 | 1,605 | 364 | 2% (26) | None | $222,613 |
| 2015 | 1,897 | 364 | 2% (38) | None | $227,467 |
| 2014 | 1,293 | 292 | 2% (19) | None | $140,409 |
| 2013 | 791 | 209 | 3% (25) | None | $77,643 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 20 drugs
| Xtandi | 11 | $168,918 | $15,356 |
| Myrbetriq | 48 | $49,089 | $1,023 |
| Alfuzosin Hcl Er | 486 | $20,378 | $42 |
| Solifenacin | 75 | $12,580 | $168 |
| Tamsulosin | 333 | $11,352 | $34 |
| Methenamine Hippurate | 95 | $9,424 | $99 |
| Fesoterodine Fumarate Er | 12 | $9,379 | $782 |
| Silodosin | 59 | $8,763 | $149 |
| Estradiol | 86 | $8,703 | $101 |
| Tolterodine Tartrate Er | 11 | $4,531 | $412 |
| Oxybutynin Chloride Er | 75 | $3,945 | $53 |
| Finasteride | 162 | $3,611 | $22 |
| Nitrofurantoin | 42 | $3,096 | $74 |
| Dutasteride | 12 | $1,691 | $141 |
| Nitrofurantoin Mono-Macro | 56 | $1,098 | $20 |
| Sulfamethoxazole-Trimethoprim | 150 | $687 | $5 |
| Ciprofloxacin | 64 | $301 | $5 |
| Cyclobenzaprine | 12 | $253 | $21 |
| Hydrocodone-Acetaminophen | 39 | $145 | $4 |
| Sildenafil Citrate | 14 | $94 | $7 |
2022: 20 drugs
| Xtandi | 24 | $346,789 | $14,450 |
| Myrbetriq | 48 | $50,965 | $1,062 |
| Alfuzosin Hcl Er | 398 | $13,593 | $34 |
| Silodosin | 61 | $10,933 | $179 |
| Methenamine Hippurate | 69 | $8,378 | $121 |
| Solifenacin | 66 | $7,634 | $116 |
| Tamsulosin | 265 | $6,905 | $26 |
| Estradiol | 59 | $6,218 | $105 |
| Tolterodine Tartrate Er | 14 | $5,070 | $362 |
| Oxybutynin Chloride Er | 71 | $3,797 | $53 |
| Finasteride | 177 | $3,304 | $19 |
| Nitrofurantoin | 43 | $3,091 | $72 |
| Potassium Citrate Er | 15 | $1,744 | $116 |
| Dutasteride | 12 | $1,528 | $127 |
| Nitrofurantoin Mono-Macro | 38 | $1,163 | $31 |
| Sulfamethoxazole-Trimethoprim | 144 | $579 | $4 |
| Cephalexin | 16 | $436 | $27 |
| Hydrocodone-Acetaminophen | 63 | $363 | $6 |
| Ciprofloxacin | 48 | $308 | $6 |
| Cyclobenzaprine | 20 | $305 | $15 |
2021: 21 drugs
| Xtandi | 25 | $336,785 | $13,471 |
| Myrbetriq | 102 | $84,392 | $827 |
| Alfuzosin Hcl Er | 311 | $12,099 | $39 |
| Silodosin | 68 | $11,581 | $170 |
| Estradiol | 52 | $7,530 | $145 |
| Solifenacin | 39 | $6,415 | $164 |
| Tamsulosin | 251 | $5,555 | $22 |
| Tolterodine Tartrate Er | 15 | $4,824 | $322 |
| Methenamine Hippurate | 35 | $4,382 | $125 |
| Finasteride | 188 | $3,871 | $21 |
| Oxybutynin Chloride Er | 59 | $3,525 | $60 |
| Potassium Citrate Er | 19 | $3,080 | $162 |
| Nitrofurantoin | 31 | $3,038 | $98 |
| Dutasteride | 19 | $2,524 | $133 |
| Sulfamethoxazole-Trimethoprim | 112 | $516 | $5 |
| Nitrofurantoin Mono-Macro | 19 | $362 | $19 |
| Hydrocodone-Acetaminophen | 51 | $347 | $7 |
| Ciprofloxacin | 59 | $279 | $5 |
| Terazosin | 11 | $274 | $25 |
| Cyclobenzaprine | 18 | $229 | $13 |
| Cephalexin | 17 | $126 | $7 |
2020: 22 drugs
| Xtandi | 23 | $290,935 | $12,649 |
| Myrbetriq | 116 | $77,971 | $672 |
| Silodosin | 66 | $10,765 | $163 |
| Solifenacin | 55 | $10,349 | $188 |
| Alfuzosin Hcl Er | 332 | $8,710 | $26 |
| Toviaz | 15 | $8,330 | $555 |
| Elmiron | 11 | $5,961 | $542 |
| Tamsulosin | 246 | $5,161 | $21 |
| Estradiol | 33 | $5,098 | $154 |
| Estrace | 11 | $3,923 | $357 |
| Methenamine Hippurate | 30 | $2,959 | $99 |
| Dutasteride | 26 | $2,845 | $109 |
| Oxybutynin Chloride Er | 58 | $2,758 | $48 |
| Potassium Citrate Er | 15 | $2,620 | $175 |
| Finasteride | 138 | $2,196 | $16 |
| Tolterodine Tartrate Er | 12 | $1,806 | $150 |
| Nitrofurantoin | 17 | $1,434 | $84 |
| Nitrofurantoin Mono-Macro | 36 | $835 | $23 |
| Ciprofloxacin | 76 | $337 | $4 |
| Sulfamethoxazole-Trimethoprim | 75 | $336 | $4 |
| Terazosin | 20 | $304 | $15 |
| Hydrocodone-Acetaminophen | 45 | $271 | $6 |
2019: 23 drugs
| Xtandi | 20 | $173,514 | $8,676 |
| Myrbetriq | 62 | $44,693 | $721 |
| Vesicare | 54 | $32,249 | $597 |
| Silodosin | 57 | $10,970 | $192 |
| Solifenacin | 37 | $10,140 | $274 |
| Toviaz | 18 | $9,176 | $510 |
| Alfuzosin Hcl Er | 256 | $8,474 | $33 |
| Estradiol | 47 | $8,212 | $175 |
| Tamsulosin | 206 | $5,544 | $27 |
| Estrace | 11 | $3,690 | $335 |
| Finasteride | 122 | $3,415 | $28 |
| Oxybutynin Chloride Er | 62 | $3,154 | $51 |
| Monurol | 11 | $2,901 | $264 |
| Methenamine Hippurate | 22 | $2,194 | $100 |
| Nitrofurantoin | 26 | $1,942 | $75 |
| Dutasteride | 14 | $1,565 | $112 |
| Potassium Citrate Er | 16 | $1,340 | $84 |
| Ciprofloxacin | 119 | $671 | $6 |
| Nitrofurantoin Mono-Macro | 28 | $633 | $23 |
| Doxazosin Mesylate | 12 | $497 | $41 |
| Sulfamethoxazole-Trimethoprim | 36 | $272 | $8 |
| Hydrocodone-Acetaminophen | 41 | $258 | $6 |
| Cephalexin | 14 | $104 | $7 |
2018: 20 drugs
| Xtandi | 12 | $131,918 | $10,993 |
| Myrbetriq | 88 | $58,437 | $664 |
| Vesicare | 76 | $45,599 | $600 |
| Rapaflo | 94 | $41,642 | $443 |
| Alfuzosin Hcl Er | 225 | $7,839 | $35 |
| Tamsulosin | 171 | $4,721 | $28 |
| Methenamine Hippurate | 37 | $4,547 | $123 |
| Oxybutynin Chloride Er | 82 | $3,915 | $48 |
| Estrace | 12 | $3,813 | $318 |
| Estradiol | 11 | $2,516 | $229 |
| Dutasteride | 25 | $2,428 | $97 |
| Finasteride | 119 | $2,201 | $18 |
| Nitrofurantoin | 18 | $1,583 | $88 |
| Ciprofloxacin | 103 | $662 | $6 |
| Doxazosin Mesylate | 18 | $649 | $36 |
| Nitrofurantoin Mono-Macro | 22 | $453 | $21 |
| Hydrocodone-Acetaminophen | 44 | $258 | $6 |
| Terazosin | 22 | $221 | $10 |
| Cephalexin | 23 | $124 | $5 |
| Sulfamethoxazole-Trimethoprim | 14 | $51 | $4 |
2017: 24 drugs
| Vesicare | 98 | $46,987 | $479 |
| Myrbetriq | 83 | $43,886 | $529 |
| Rapaflo | 97 | $41,787 | $431 |
| Estrace | 30 | $8,698 | $290 |
| Alfuzosin Hcl Er | 244 | $6,433 | $26 |
| Tamsulosin | 204 | $5,189 | $25 |
| Oxybutynin Chloride Er | 89 | $4,270 | $48 |
| Methenamine Hippurate | 28 | $3,078 | $110 |
| Dutasteride | 12 | $2,428 | $202 |
| Nitrofurantoin | 27 | $2,123 | $79 |
| Finasteride | 115 | $2,091 | $18 |
| Dutasteride-Tamsulosin | 12 | $1,491 | $124 |
| Doxazosin Mesylate | 39 | $1,255 | $32 |
| Ciprofloxacin | 133 | $709 | $5 |
| Oxybutynin Chloride | 23 | $587 | $26 |
| Terazosin | 60 | $409 | $7 |
| Nitrofurantoin Mono-Macro | 13 | $396 | $30 |
| Bicalutamide | 12 | $280 | $23 |
| Hydrocodone-Acetaminophen | 44 | $274 | $6 |
| Cyclobenzaprine | 13 | $234 | $18 |
| Amitriptyline | 13 | $154 | $12 |
| Nystatin | 16 | $101 | $6 |
| Cephalexin | 15 | $80 | $5 |
| Sulfamethoxazole-Trimethoprim | 16 | $54 | $3 |
2016: 22 drugs
| Vesicare | 103 | $48,784 | $474 |
| Rapaflo | 156 | $47,371 | $304 |
| Myrbetriq | 61 | $27,756 | $455 |
| Tamsulosin | 281 | $9,196 | $33 |
| Oxybutynin Chloride Er | 77 | $4,253 | $55 |
| Alfuzosin Hcl Er | 180 | $4,145 | $23 |
| Estrace | 14 | $3,741 | $267 |
| Methenamine Hippurate | 25 | $3,019 | $121 |
| Doxazosin Mesylate | 48 | $2,315 | $48 |
| Finasteride | 123 | $1,999 | $16 |
| Oxybutynin Chloride | 67 | $1,795 | $27 |
| Nitrofurantoin | 29 | $1,567 | $54 |
| Bicalutamide | 25 | $893 | $36 |
| Desmopressin Acetate | 16 | $604 | $38 |
| Ciprofloxacin | 103 | $529 | $5 |
| Terazosin | 76 | $450 | $6 |
| Amitriptyline | 14 | $272 | $19 |
| Hydrocodone-Acetaminophen | 25 | $254 | $10 |
| Lidocaine | 13 | $210 | $16 |
| Cephalexin | 23 | $145 | $6 |
| Nystatin | 11 | $102 | $9 |
| Sulfamethoxazole-Trimethoprim | 23 | $90 | $4 |
2015: 25 drugs
| Rapaflo | 305 | $83,594 | $274 |
| Vesicare | 137 | $52,578 | $384 |
| Myrbetriq | 38 | $19,332 | $509 |
| Avodart | 57 | $13,698 | $240 |
| Tamsulosin | 321 | $11,845 | $37 |
| Toviaz | 17 | $7,463 | $439 |
| Premarin | 19 | $4,812 | $253 |
| Methenamine Hippurate | 28 | $3,383 | $121 |
| Finasteride | 179 | $3,101 | $17 |
| Oxybutynin Chloride Er | 57 | $2,982 | $52 |
| Jalyn | 14 | $2,948 | $211 |
| Alfuzosin Hcl Er | 119 | $2,602 | $22 |
| Doxazosin Mesylate | 58 | $2,266 | $39 |
| Oxybutynin Chloride | 87 | $2,262 | $26 |
| Flutamide | 12 | $1,427 | $119 |
| Desmopressin Acetate | 14 | $906 | $65 |
| Bethanechol Chloride | 11 | $732 | $67 |
| Bicalutamide | 23 | $585 | $25 |
| Ciprofloxacin | 125 | $578 | $5 |
| Terazosin | 74 | $418 | $6 |
| Nitrofurantoin Mono-Macro | 15 | $392 | $26 |
| Amitriptyline | 16 | $310 | $19 |
| Hydrocodone-Acetaminophen | 38 | $242 | $6 |
| Cephalexin | 20 | $123 | $6 |
| Sulfamethoxazole-Trimethoprim | 32 | $114 | $4 |
2014: 19 drugs
| Rapaflo | 240 | $56,872 | $237 |
| Avodart | 117 | $24,364 | $208 |
| Vesicare | 57 | $16,299 | $286 |
| Tamsulosin | 215 | $5,940 | $28 |
| Myrbetriq | 12 | $5,587 | $466 |
| Methenamine Hippurate | 42 | $5,093 | $121 |
| Toviaz | 11 | $4,531 | $412 |
| Premarin | 17 | $3,794 | $223 |
| Oxybutynin Chloride Er | 50 | $3,178 | $64 |
| Doxazosin Mesylate | 60 | $2,715 | $45 |
| Finasteride | 121 | $2,169 | $18 |
| Alfuzosin Hcl Er | 41 | $1,489 | $36 |
| Oxybutynin Chloride | 33 | $981 | $30 |
| Ciprofloxacin | 81 | $395 | $5 |
| Terazosin | 28 | $229 | $8 |
| Cephalexin | 20 | $167 | $8 |
| Levofloxacin | 18 | $133 | $7 |
| Amitriptyline | 16 | $132 | $8 |
| Hydrocodone-Acetaminophen | 17 | $129 | $8 |
2013: 13 drugs
| Avodart | 113 | $22,152 | $196 |
| Rapaflo | 78 | $18,960 | $243 |
| Vesicare | 47 | $12,442 | $265 |
| Methenamine Hippurate | 39 | $5,602 | $144 |
| Oxybutynin Chloride Er | 32 | $2,880 | $90 |
| Tamsulosin | 122 | $2,566 | $21 |
| Finasteride | 33 | $1,744 | $53 |
| Doxazosin Mesylate | 59 | $1,206 | $20 |
| Ciprofloxacin | 96 | $528 | $5 |
| Levofloxacin | 16 | $149 | $9 |
| Cephalexin | 20 | $129 | $6 |
| Hydrocodone-Acetaminophen | 25 | $110 | $4 |
| Amitriptyline | 13 | $81 | $6 |
Money from drug and device companies
$1,316 in 2025
| 2025 | 23 | 41 | None | $1,316 |
| 2024 | 21 | 46 | $255 | $1,467 |
| 2023 | 21 | 58 | $1,870 | $3,487 |
| 2022 | 17 | 90 | None | $1,465 |
| 2021 | 18 | 96 | None | $1,596 |
| 2020 | 10 | 62 | None | $788 |
| 2019 | 10 | 42 | None | $719 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Interstim | $276 | 7 payments
|
| Astellas Pharma US | Xtandi | $189 | 4 payments
|
| Janssen Biotech | Erleada | $133 | 4 payments
|
| Seagen | None | $100 | 1 payment
|
| Pfizer | Xtandi | $98 | 4 payments
|
| Novartis Pharmaceuticals | Pluvicto | $64 | 2 payments
|
See all 41 published payments
| Medtronic | Meals · 2025-12-20 | Interstim | $103 |
| Novartis Pharmaceuticals | Meals · 2025-12-08 | Pluvicto | $33 |
| Medtronic | Meals · 2025-11-20 | Altaviva | $6 |
| Medtronic | Meals · 2025-10-31 | Altaviva | $8 |
| Medtronic | Meals · 2025-10-31 | Altaviva | $8 |
| Janssen Biotech | Meals · 2025-10-24 | Erleada | $35 |
| Pfizer | Meals · 2025-10-03 | Xtandi | $23 |
| Urogen Pharma | Meals · 2025-09-23 | Zusduri | $18 |
| Novartis Pharmaceuticals | Meals · 2025-09-18 | Pluvicto | $30 |
| Seagen | Education · 2025-09-03 | None | $100 |
| Medtronic | Meals · 2025-08-22 | Interstim | $13 |
| Teleflex | Meals · 2025-08-15 | Barrigel | $32 |
| 180 Medical | Meals · 2025-08-14 | None | $28 |
| Janssen Biotech | Meals · 2025-08-01 | Erleada | $35 |
| Medtronic | Meals · 2025-08-01 | Interstim | $9 |
| Abbvie | Meals · 2025-07-31 | Lupron Depot | $23 |
| Pfizer | Meals · 2025-07-25 | Xtandi | $25 |
| Astellas Pharma US | Meals · 2025-07-23 | Xtandi | $29 |
| Endo USA | Meals · 2025-07-18 | Xiaflex | $25 |
| Immunitybio | Meals · 2025-07-17 | Anktiva | $27 |
| Abbvie | Meals · 2025-07-10 | Botox | $32 |
| Dentsply Ih Ab | Meals · 2025-06-26 | Lofric | $15 |
| Procept Biorobotics | Meals · 2025-06-12 | Aquabeam Robotic System | $23 |
| Endo USA | Meals · 2025-06-06 | Xiaflex | $29 |
| Janssen Biotech | Meals · 2025-06-05 | Erleada | $30 |
| Astellas Pharma US | Education · 2025-06-03 | None | $100 |
| Astellas Pharma US | Meals · 2025-05-15 | Xtandi | $25 |
| Pfizer | Meals · 2025-04-18 | Xtandi | $24 |
| Boston Scientific | Meals · 2025-04-17 | Ams 700 | $26 |
| Sumitomo Pharma America | Meals · 2025-04-15 | Orgovyx | $20 |
| Cook Medical | Meals · 2025-03-10 | Cook | $26 |
| Olympus America | Meals · 2025-03-06 | Itind System | $17 |
| Laborie Medical Technologies | Meals · 2025-02-13 | Optilume Bph Drug Coated Balloon Catheter | $18 |
| Smith+Nephew | Meals · 2025-02-12 | Stravix Pl | $31 |
| Medtronic | Meals · 2025-02-07 | Interstim | $130 |
| Sagent Pharmaceuticals | Meals · 2025-02-07 | Glydo | $19 |
| Janssen Biotech | Meals · 2025-02-06 | Erleada | $33 |
| Pfizer | Meals · 2025-01-31 | Xtandi | $25 |
| Coloplast | Meals · 2025-01-27 | Titan | $21 |
| Progenics Pharmaceuticals | Meals · 2025-01-24 | Pylarify | $27 |
| Astellas Pharma US | Meals · 2025-01-16 | Xtandi | $34 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,467
| Coloplast | Luja Coude | $348 | 10 payments
|
| PROCEPT BioRobotics | Aquabeam System | $180 | 3 payments
|
| Medtronic | Interstim | $138 | 1 payment
|
| Abbvie | Botox | $95 | 4 payments
|
| Axonics | Axonics | $90 | 3 payments
|
| Boston Scientific | Ams 700 | $75 | 2 payments
|
| Endo USA | Xiaflex | $68 | 3 payments
|
| Accord Healthcare | Camcevi | $66 | 3 payments
|
| Astellas Pharma US | Xtandi | $59 | 2 payments
|
| Janssen Biotech | Erleada | $56 | 2 payments
|
| Endo Pharmaceuticals | Xiaflex | $42 | 2 payments
|
| Myriad Genetic Laboratories | Prolaris | $39 | 2 payments
|
| Blue Earth Diagnostics | Posluma | $29 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $28 | 1 payment
|
| Pfizer | Xtandi | $28 | 1 payment
|
| Urogen Pharma | Jelmyto | $27 | 1 payment
|
| ConvaTec | Cure Ultra Catheter | $26 | 1 payment
|
| Verity Pharmaceuticals | Trelstar | $23 | 1 payment
|
| Olympus America | Itind System | $19 | 1 payment
|
| Bluewind Medical | Revi | $16 | 1 payment
|
| C. R. Bard Inc. & Subsidiaries | Bard Urinary Drainage Bag | $15 | 1 payment
|
2023: $3,487
| Coloplast | Luja Coude | $2,139 | 8 payments
|
| Janssen Biotech | Erleada | $326 | 11 payments
|
| Progenics Pharmaceuticals | Pylarify | $180 | 4 payments
|
| AbbVie | Botox | $131 | 6 payments
|
| Medtronic | Interstim | $102 | 1 payment
|
| Axonics | Axonics | $89 | 3 payments
|
| Astellas Pharma US | Xtandi | $78 | 3 payments
|
| Endo Pharmaceuticals | Xiaflex | $74 | 4 payments
|
| C. R. Bard Inc. & Subsidiaries | Bard Urinary Drainage Bag | $46 | 3 payments
|
| Davol | None | $45 | 1 payment
|
| Sumitomo Pharma America | Gemtesa | $39 | 2 payments
|
| UroGen Pharma | Jelmyto | $36 | 2 payments
|
| Teleflex | Urolift | $32 | 2 payments
|
| 180 Medical | None | $27 | 1 payment
|
| Dendreon Pharmaceuticals | Provenge | $27 | 1 payment
|
| Boston Scientific | Ams 800 Artificial Urinary Sphincter | $22 | 1 payment
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $22 | 1 payment
|
| Accord Healthcare | Camcevi | $20 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $19 | 1 payment
|
| Olympus America | Itind System | $18 | 1 payment
|
| Tolmar | Eligard | $16 | 1 payment
|
2022: $1,465
| Rochester Medical | None | $235 | 31 payments
|
| Coloplast | Speedicath | $225 | 8 payments
|
| Janssen Biotech | Erleada | $195 | 10 payments
|
| Medtronic | Interstim | $151 | 4 payments
|
| Abbvie | Botox | $143 | 9 payments
|
| Astellas Pharma US | Myrbetriq | $135 | 10 payments
|
| Endo Pharmaceuticals | Xiaflex | $81 | 4 payments
|
| Acerus Pharmaceuticals | Natesto | $50 | 2 payments
|
| Myovant Sciences | Orgovyx | $45 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $42 | 2 payments
|
| Smith+Nephew | Grafix Pl | $42 | 2 payments
|
| Accord Healthcare | Camcevi | $24 | 1 payment
|
| UroGen Pharma | Jelmyto | $22 | 1 payment
|
| Photocure | Cysview | $21 | 1 payment
|
| Olympus America | Itind System | $21 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $20 | 1 payment
|
| ABC Home Medical Supply | None | $12 | 1 payment
|
2021: $1,596
| Coloplast | Speedicath | $402 | 50 payments
|
| Myriad Genetic Laboratories | Prolaris | $294 | 4 payments
|
| Medtronic | Interstim | $198 | 5 payments
|
| Janssen Biotech | Erleada | $120 | 7 payments
|
| Myovant Sciences | Orgovyx | $103 | 5 payments
|
| Pfizer | Xtandi | $81 | 4 payments
|
| Endo Pharmaceuticals | Aveed | $70 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $55 | 3 payments
|
| Allergan | Botox | $40 | 2 payments
|
| Astellas Pharma US | Xtandi | $40 | 2 payments
|
| Acerus Pharmaceuticals | Natesto | $34 | 2 payments
|
| Axonics | Axonics R-Snm System | $28 | 2 payments
|
| Rochester Medical | None | $26 | 2 payments
|
| AbbVie | None | $25 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $23 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $21 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $21 | 1 payment
|
| Teleflex | Urolift System | $16 | 1 payment
|
2020: $788
| Coloplast | Continence Care | $199 | 22 payments
|
| Endo Pharmaceuticals | Aveed | $198 | 13 payments
|
| Medtronic USA | Interstim | $121 | 12 payments
|
| Astellas Pharma US | Myrbetriq | $61 | 3 payments
|
| Pfizer | Xtandi | $59 | 4 payments
|
| AbbVie | Lupron Depot | $49 | 3 payments
|
| Allergan | Botox | $36 | 2 payments
|
| Boston Scientific | Ams | $25 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $22 | 1 payment
|
| NeoTract | Urolift | $19 | 1 payment
|
2019: $719
| Medtronic USA | Interstim | $233 | 10 payments
|
| Endo Pharmaceuticals | Aveed | $140 | 10 payments
|
| Coloplast | Speedicath | $114 | 11 payments
|
| Allergan | Botox | $84 | 4 payments
|
| Boston Scientific | General Bph | $49 | 2 payments
|
| Astellas Pharma US | Xtandi | $25 | 1 payment
|
| AbbVie | Lupron Depot | $24 | 1 payment
|
| Olympus America | Olympus Cystoscopes | $21 | 1 payment
|
| Pfizer | Xtandi | $17 | 1 payment
|
| 180 Medical | Gentlecath | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Alnylam Pharmaceuticals Inc. · A Study To Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels · 2022 | Their institution | $20,000 |
| Veru Inc. · Veracity - Randomized, Active-Controlled, Phase 3 Study of Veru-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent · 2023 | Their institution | $10,300 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1093882995
- Licence
- CA A48911California A48911: Current · expires 2028-09-30
- Group
- Sherif Aboseif MD Inc · Genesis Healthcare Partners PC
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 1901 Holser Walk Ste 310, Oxnard, CA, 93036
- NPI first listed
- 2006-11-29
- NPI last updated
- 2020-07-13
- NPI record certified
- 2020-07-13
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.